C.H. Robinson suspends repurchases post RXO acquisition: Can CHRW sustain this weak momentum?

C.H. Robinson suspends repurchases post RXO acquisition: Can CHRW sustain this weak momentum?
C.H. Robinson drops 10.04% after earnings

C.H. Robinson (CHRW) stock is trading at $129.18, down 10.04% on the day. The price action sits below its key moving averages, reflecting ongoing weakness after a sharp intraday drop.

CHRW price prediction
24H -1.41%
$122.85
48H -1.6%
$122.62
7D -0.81%
$123.6
1M -4.66%
$118.8
3M 2.58%
$127.83
6M 5.59%
$131.57
12M -4.02%
$119.6
Current price: $124.61 -2.6950 2.12%
Closed 10/30
Daily range 122.21 Arrow from to Icon 128.42
Weekly range 122.21 Arrow from to Icon 144.13
Loading...

Highlights

  • C.H. Robinson reported third quarter revenue up 29.5% year over year to $5.36 billion and adjusted earnings per share of $1.80, both above expectations.
  • The company suspended its share repurchase program and faces increased deal execution risk related to the planned RXO acquisition.
  • Shares of C.H. Robinson fell 10.04% to $129.18, trading below key moving averages with strong bearish momentum and an expected range of $113.44 to $131.42.

Buyback halt and deal risks weigh despite strong Q3 results

C.H. Robinson reported strong financial results for the third quarter of 2026, with revenue rising 29.5% year-over-year to $5.36 billion and adjusted earnings per share of $1.80, both exceeding market expectations, according to Gurufocus. Despite these robust figures, the company has paused its share repurchase program following the agreement to acquire RXO, introducing added uncertainty over capital deployment and deal execution risk. The buyback suspension, along with investor concerns surrounding leverage and the RXO transaction, contributed to a cautious market reaction as noted by Seeking Alpha.

CH Robinson Worldwide Inc asset chart
CH Robinson Worldwide Inc price dynamics. Source: TradingView.

Downtrend momentum intensifies as all indicators flag persistent weakness

The price is trading below the MA-20 ($139.76), MA-50 ($140.38), and MA-200 ($170.23). The Ichimoku Kijun at $135.14 stands as immediate resistance. Momentum indicators present a strongly bearish picture: MACD remains on Sell, ADX is Neutral without highlighting a clear trend, and RSI, Stoch RSI, CCI, and Bull/Bear Power all signal oversold conditions and ongoing seller dominance. The stock is pinned near today’s low with high volatility and no bullish divergence on momentum signals.

Downside overshoot risk rises as volatility constrains upside

In the near term, CHRW is expected to trade within a range of $113.44 to $131.42, with roughly a 79% probability of further downside and only a 21% chance of a short-term upward move. The baseline scenario sees the price moving sideways within this band as volatility settles. A break above the $135.14 resistance would open room for a bullish reversal, while a drop below $113.44 would indicate further downside overshoot.

Anton Kharitonov, analyst at Traders Union, sees the recent earnings beat as fundamentally strong but overshadowed by concerns about capital allocation and deal risks. He notes persistent bearish momentum in both price and indicators, with the paused buyback compounding investor caution. For now, he believes the technical setup points to further downside or sideways movement unless resistance at $135.14 is reclaimed. "Until the stock reclaims the $135.14 level and resolves buyback and acquisition uncertainty, I stay defensive on CHRW."

Earlier, analysts noted that heightened leverage and integration risks from the RXO acquisition were driving a persistently bearish outlook for C.H. Robinson shares. The current analysis reinforces this view, with ongoing technical weakness and a suspended buyback signaling elevated downside risk, making the $113.44 support a critical level for traders to monitor in the sessions ahead.

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.